Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CASI PharmaceuticalsCASIF 29 3-Year EBITDA Growth Rate is 2.70% as of Dec. 2025, which is 79% below its 10-year median of 12.80. GuruFocus rates CASIF with a GF Score™ of 29/100 and a GF Value™ of $1.10 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,136 Biotechnology companies, CASI Pharmaceuticals ranks worse than 66.02% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 2.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 4.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -0.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of CASI Pharmaceuticals was 51.10% per year. The lowest was -62.80% per year. And the median was 12.80% per year.
CASI Pharmaceuticals (OTCPK:CASIF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
CASI Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
CASIF vs DCOY, PKTX, BIXT: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, CASI Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
CASI Pharmaceuticals 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 2.70% mean?
CASI Pharmaceuticals (CASIF) has a 3-Year EBITDA Growth Rate of 2.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CASI Pharmaceuticals and its competitors. This is 79% below median its historical median of 12.80. According to the industry distribution chart, CASI Pharmaceuticals ranks #750 out of 1136 companies in the Biotechnology industry, placing it in the top 66%.
Is CASI Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
CASI Pharmaceuticals' current 3-Year EBITDA Growth Rate of 2.70% is 79% below median its 10-year median of 12.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. CASI Pharmaceuticals' value of 2.70% is 81.8% below this industry median. Based on the distribution chart, CASI Pharmaceuticals ranks #750 out of 1136 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' 3-Year EBITDA Growth Rate compare to DCOY and PKTX?
According to the Biotechnology industry distribution chart, CASI Pharmaceuticals ranks #750 out of 1136 companies for 3-Year EBITDA Growth Rate. This places CASI Pharmaceuticals in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. CASI Pharmaceuticals' value of 2.70% is 81.8% below this benchmark. While the company's 10-year median is 12.80 vs. the industry median of 14.85, CASI Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CASI Pharmaceuticals's current 3-Year EBITDA Growth Rate of 2.70% is 81.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CASI Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CASI Pharmaceuticals's current 3-Year EBITDA Growth Rate is 2.70%, which is 79% below median its own 10-year median of 12.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CASI Pharmaceuticals (CASIF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.10, compared to a current price of $0.13 — trading 88.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 2.70%, which is 79% below median its 10-year median of 12.80 and 81.8% below the Biotechnology industry median of 14.85. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For CASI Pharmaceuticals (CASIF), the current 3-Year EBITDA Growth Rate is 2.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.13 is trading 88.3% below its estimated GF Value™ of $1.10.
GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.
Key valuation signals for CASIF:
3-Year EBITDA Growth Rate: 2.70% (79% below median its 10-year median of 12.80)
GF Value™: $1.10 vs. price of $0.13 (88.3% below fair value)
Industry Position: 81.8% below the Biotechnology median (#750 of 1136)
No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score
Get the complete analysis for CASIF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASIF has been successfully added to your 
